# Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

> **NCT03559049** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT03559049
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-24
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Due to financial hardships suffered by the stakeholder
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03559049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03559049, "Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03559049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*